DDInter704 DDInter489
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA approved on October 14, 2011.
Everolimus {u} (Compound) causes {v} (Side Effect) Connective tissue disorder
Connective tissue disorder {u} (Side Effect) is caused by {v} (Compound) Deferiprone
Everolimus {u} (Compound) causes {v} (Side Effect) Connective tissue disorder
Connective tissue disorder {u} (Side Effect) is caused by {v} (Compound) Bexarotene
Bexarotene {u} may lead to a major life threatening interaction when taken with {v} Deferiprone
Everolimus {u} (Compound) causes {v} (Side Effect) Diarrhoea
Diarrhoea {u} (Side Effect) is caused by {v} (Compound) Didanosine
Didanosine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Deferiprone
Everolimus {u} (Compound) downregulates {v} (Gene) POLE2
POLE2 {u} (Gene) is regulated by {v} (Gene) UGT1A6
UGT1A6 {u} (Gene) is bound by {v} (Compound) Deferiprone
Everolimus {u} (Compound) upregulates {v} (Gene) KLHL21
KLHL21 {u} (Gene) is regulated by {v} (Gene) UGT1A6
UGT1A6 {u} (Gene) is bound by {v} (Compound) Deferiprone
Everolimus {u} (Compound) downregulates {v} (Gene) POLE2
POLE2 {u} (Gene) is downregulated by {v} (Compound) Azacitidine
Azacitidine {u} may lead to a major life threatening interaction when taken with {v} Deferiprone
Everolimus {u} (Compound) upregulates {v} (Gene) KLHL21
KLHL21 {u} (Gene) is upregulated by {v} (Compound) Mitomycin
Mitomycin {u} may lead to a major life threatening interaction when taken with {v} Deferiprone
Everolimus {u} (Compound) downregulates {v} (Gene) POLE2
POLE2 {u} (Gene) is bound by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Deferiprone
Everolimus {u} (Compound) downregulates {v} (Gene) PDHX
PDHX {u} (Gene) is regulated by {v} (Gene) BTK
BTK {u} (Gene) is upregulated by {v} (Compound) Deferiprone
Everolimus {u} (Compound) causes {v} (Side Effect) Atrial fibrillation
Atrial fibrillation {u} (Side Effect) is caused by {v} (Compound) Ponatinib
Ponatinib {u} may lead to a major life threatening interaction when taken with {v} Deferiprone
Everolimus (Compound) causes Connective tissue disorder (Side Effect) and Connective tissue disorder (Side Effect) is caused by Deferiprone (Compound)
Everolimus (Compound) causes Connective tissue disorder (Side Effect) and Connective tissue disorder (Side Effect) is caused by Bexarotene (Compound) and Bexarotene may lead to a major life threatening interaction when taken with Deferiprone
Everolimus (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Didanosine (Compound) and Didanosine may cause a moderate interaction that could exacerbate diseases when taken with Deferiprone
Everolimus (Compound) downregulates POLE2 (Gene) and POLE2 (Gene) is regulated by UGT1A6 (Gene) and UGT1A6 (Gene) is bound by Deferiprone (Compound)
Everolimus (Compound) upregulates KLHL21 (Gene) and KLHL21 (Gene) is regulated by UGT1A6 (Gene) and UGT1A6 (Gene) is bound by Deferiprone (Compound)
Everolimus (Compound) downregulates POLE2 (Gene) and POLE2 (Gene) is downregulated by Azacitidine (Compound) and Azacitidine may lead to a major life threatening interaction when taken with Deferiprone
Everolimus (Compound) upregulates KLHL21 (Gene) and KLHL21 (Gene) is upregulated by Mitomycin (Compound) and Mitomycin may lead to a major life threatening interaction when taken with Deferiprone
Everolimus (Compound) downregulates POLE2 (Gene) and POLE2 (Gene) is bound by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Deferiprone
Everolimus (Compound) downregulates PDHX (Gene) and PDHX (Gene) is regulated by BTK (Gene) and BTK (Gene) is upregulated by Deferiprone (Compound)
Everolimus (Compound) causes Atrial fibrillation (Side Effect) and Atrial fibrillation (Side Effect) is caused by Ponatinib (Compound) and Ponatinib may lead to a major life threatening interaction when taken with Deferiprone